Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

INMB vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 41.5 SELL), While INMB Leads 3–1 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: INMB 3 – 1 ATYR (2 Tie) Matrix Metrics: INMB 5 – 1 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. INMB trades at $0.96 (N/M Forward P/E, 0.0% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY).
  • Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both INMB (41.5/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: INMB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INMB vs ATYR
INMB NASDAQ
INmune Bio Inc. Common stock
Biological Products, (No Disgnostic Substances)
$0.96
+1.55% 1D
Market Cap $32.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.61β · 74% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 25.0 Fund 50.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.7%), weak momentum, RSI 22
RSI-14: 22.5 · SMA20: $1.29 · SMA50: $1.70
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.57β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (INMB 3 – 1 ATYR)

Columns: Metric · INMB · ATYR
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale INMB
Revenue Growth (YoY) +257.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $32.5M $15.6M
3. Profitability & Quality INMB
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -76.7% -93.7%
4. Balance Sheet & Cash Flow INMB
Cash Generation (TTM) -$13M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $15M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 326.9% (45th %ile) 154.5% (36th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INMB (5) vs ATYR (1)
Institutional Metric INMB ATYR Criterion Row Edge
Market Capitalization
Scale
$32.5M $15.6M Larger Scale INMB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+257.1% +0.0% Higher Growth INMB
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-76.7% -93.7% Higher ROE INMB
52-Week Range Position
Momentum
4% ($1–$3) 60% ($0–$8) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
2.61β · 74% Vol -9.57β · 13806% Vol Lower Realized Risk INMB
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite INMB
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$13M ($15M Net Cash) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2750.64 pp
INMB: -37.59% · ATYR: +2713.05%
3M Horizon ATYR +863.43 pp
INMB: -56.9% · ATYR: +806.53%
6M Horizon ATYR +931.84 pp
INMB: -31.84% · ATYR: +900.0%
1Y Horizon ATYR +573.75 pp
INMB: -32.32% · ATYR: +541.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period INMB Revenue ATYR Revenue INMB Op. Margin ATYR Op. Margin Margin Leader
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 $0M $10M -111163.6% -152.2% ATYR
FY2021 $0M N/A -16106.6% N/A INMB
FY2022 $0M $10M -6938.8% -446.8% ATYR
FY2023 $0M $0M -19187.7% -15557.8% ATYR
FY2024 $0M $0M -304535.7% -28899.6% ATYR
FY2025 $0M $0M -94766.0% -40856.3% ATYR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INMB BREAKDOWN
50d in phase · OBV DISTRIBUTION
Current IV 326.9%
IV Percentile 45th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INMB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $32.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INMB vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. INMB trades at $0.96 (N/M Forward P/E, 0.0% operating margin) versus ATYR at $4.83 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY). Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both INMB (41.5/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: INMB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.5); meanwhile ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INMB leads the Growth & Scale pillar: INMB posts +257.1% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), INMB cumulative revenue shifted N/A while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, INMB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

INMB and ATYR trade at balanced relative valuation multiples. INMB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INMB (-76.7% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, INMB carries 326.9% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.61β · 74% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.